0001104659-20-057878.txt : 20200507 0001104659-20-057878.hdr.sgml : 20200507 20200507105847 ACCESSION NUMBER: 0001104659-20-057878 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200507 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200507 DATE AS OF CHANGE: 20200507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INSMED Inc CENTRAL INDEX KEY: 0001104506 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 541972729 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30739 FILM NUMBER: 20855141 BUSINESS ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908-977-9900 MAIL ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: INSMED INC DATE OF NAME CHANGE: 20000128 8-K 1 tm2018832d2_8k.htm FORM 8-K
0001104506 false 0001104506 2020-05-06 2020-05-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): May 7, 2020

 

 

 

INSMED INCORPORATED

(Exact Name of Registrant as Specified in Charter)

 

 

 

Virginia   000-30739   54-1972729

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

700 US Highway 202/206

Bridgewater, New Jersey 08807

(Address of Principal Executive Offices, and Zip Code)

 

(908) 977-9900

Registrant’s Telephone Number, Including Area Code

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨      Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨      Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨      Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   INSM   Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 7.01 — Regulation FD Disclosure

 

On May 7, 2020, Insmed Incorporated (the “Company”) issued a press release announcing the closing of its public offering of 11,155,000 shares of the Company’s common stock, par value $0.01 per share. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit     Description  
99.1   Press Release issued by Insmed Incorporated on May 7, 2020.
     
104   Cover Page Interactive Date File (embedded within the Inline XBRL document).

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Dated: May 7, 2020   INSMED INCORPORATED  
   
    By: /s/ Christine Pellizzari 
    Name: Christine Pellizzari 
    Title:   Chief Legal Officer  

 

 3 

 

 EX-99.1 2 tm2018832d2_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

Insmed Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

 

BRIDGEWATER, NJ, May 7, 2020 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM) announced today the closing of the previously announced public offering of 11,155,000 shares of its common stock, including 1,455,000 shares issued pursuant to the exercise in full of the underwriters’ option to purchase additional shares, at a public offering price of $23.25 per share. The gross proceeds to Insmed from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Insmed, were approximately $259.4 million.

 

Insmed intends to use its net proceeds from this offering to continue to commercialize ARIKAYCE® (amikacin liposome inhalation suspension); conduct further trials of ARIKAYCE, including Insmed’s required confirmatory trial to assess and describe the clinical benefit of ARIKAYCE in patients with Mycobacterium avium complex (MAC) lung disease; conduct further trials of brensocatib (formerly known as INS1007), including its planned Phase 3 program in bronchiectasis; fund further clinical development of treprostinil palmitil (formerly known as INS1009); invest in third-party manufacturing capacity; fund business expansion activities in Europe and Japan; fund working capital, potential debt repayment, capital expenditures, and general research and development; and for other general corporate purposes, which may include the acquisition or in-license of additional compounds, product candidates, technology or businesses.

 

SVB Leerink acted as sole bookrunning manager for the offering. Credit Suisse and Stifel acted as co-lead managers for the offering. JMP Securities and H.C. Wainwright & Co. acted as co-managers for the offering.

 

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above has been filed with the Securities and Exchange Commission (SEC), as amended by Post-Effective Amendment No. 1 thereto, and became automatically effective upon filing on May 19, 2017. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to this offering may be obtained from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02110, by telephone: 1-800-808-7525, ext. 6218 or by email at syndicate@svbleerink.com.

 

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

 

 

 

 

About Insmed

 

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product, ARIKAYCE® (amikacin liposome inhalation suspension), is the first and only therapy approved in the United States for the treatment of refractory Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a chronic, debilitating condition that can cause severe and permanent lung damage. Insmed's earlier-stage clinical pipeline includes brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and treprostinil palmitil, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

 

Forward-looking Statements

 

This press release contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking statements.

 

 

 

 

The forward-looking statements in this press release are based upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: the risk that brensocatib does not prove effective or safe for patients in the STOP-COVID19 study; business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises; impact of the novel coronavirus (COVID-19) pandemic and efforts to reduce its spread on our business, employees, including key personnel, patients, partners and suppliers; the risk that the full data set from the WILLOW study, our six-month Phase 2 trial of brensocatib in patients with NCBFE or data generated in further clinical trials of brensocatib will not be consistent with the top-line results of the study; failure to successfully commercialize or maintain U.S. approval for ARIKAYCE, the Company's only approved product; uncertainties in the degree of market acceptance of ARIKAYCE by physicians, patients, third-party payors and others in the healthcare community; the Company's inability to obtain full approval of ARIKAYCE from the FDA, including the risk that the Company will not timely and successfully complete the study to validate a PRO tool and complete the confirmatory post-marketing study required for full approval of ARIKAYCE; inability of the Company, PARI or the Company's other third party manufacturers to comply with regulatory requirements related to ARIKAYCE or the Lamira® Nebulizer System; the Company's inability to obtain adequate reimbursement from government or third-party payors for ARIKAYCE or acceptable prices for ARIKAYCE; development of unexpected safety or efficacy concerns related to ARIKAYCE or brensocatib; inaccuracies in the Company's estimates of the size of the potential markets for ARIKAYCE or brensocatib or in data the Company has used to identify physicians; expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company's inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE; failure to obtain regulatory approval to expand ARIKAYCE's indication to a broader patient population; failure to successfully conduct future clinical trials for ARIKAYCE, brensocatib and the Company's other product candidates, including due to the Company's limited experience in conducting preclinical development activities and clinical trials necessary for regulatory approval and the Company's inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval; risks that the Company's clinical studies will be delayed or that serious side effects will be identified during drug development; failure to obtain, or delays in obtaining, regulatory approvals for ARIKAYCE outside the U.S. or for the Company's product candidates in the U.S., Europe, Japan or other markets, including the United Kingdom as a result of its recent exit from the European Union; failure of third parties on which the Company is dependent to manufacture sufficient quantities of ARIKAYCE or the Company's product candidates for commercial or clinical needs, to conduct the Company's clinical trials, or to comply with laws and regulations that impact the Company's business or agreements with the Company; the Company's inability to attract and retain key personnel or to effectively manage the Company's growth; the Company's inability to adapt to its highly competitive and changing environment; the Company's inability to adequately protect its intellectual property rights or prevent disclosure of its trade secrets and other proprietary information and costs associated with litigation or other proceedings related to such matters; restrictions or other obligations imposed on the Company by its agreements related to ARIKAYCE or the Company's product candidates, including its license agreements with PARI and AstraZeneca AB, and failure of the Company to comply with its obligations under such agreements; the cost and potential reputational damage resulting from litigation to which the Company is or may become a party, including product liability claims; the Company's limited experience operating internationally; changes in laws and regulations applicable to the Company's business, including any pricing reform, and failure to comply with such laws and regulations; inability to repay the Company's existing indebtedness and uncertainties with respect to the Company's ability to access future capital; and delays in the execution of plans to build out an additional FDA-approved third-party manufacturing facility and unexpected expenses associated with those plans. 

 

The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company's forward-looking statements because, by their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For additional information about the risks and uncertainties that may affect the Company's business, please see the factors discussed in Item 1A, "Risk Factors," in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 and any subsequent Company filings with the SEC.

 

 

 

 

The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

 

Contact:

 

Investors:

 

Argot Partners
Laura Perry or Heather Savelle
(212) 600-1902
insmed@argotpartners.com

 

Media:

 

Mandy Fahey

Senior Director, Corporate Communications

Insmed

(732) 718-3621

amanda.fahey@insmed.com

 

 

 EX-101.SCH 3 insm-20200507.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 insm-20200507_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 insm-20200507_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2018832d2_ex99-1img001.jpg GRAPHIC begin 644 tm2018832d2_ex99-1img001.jpg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end EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://insmed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2018832d2_8k.htm insm-20200507.xsd insm-20200507_lab.xml insm-20200507_pre.xml tm2018832d2_ex99-1.htm http://xbrl.sec.gov/dei/2019-01-31 true false ZIP 12 0001104659-20-057878-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-057878-xbrl.zip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end XML 13 tm2018832d2_8k_htm.xml IDEA: XBRL DOCUMENT 0001104506 2020-05-06 2020-05-07 iso4217:USD shares iso4217:USD shares 0001104506 false 8-K 2020-05-07 INSMED INCORPORATED VA 000-30739 54-1972729 700 US Highway 202/206 Bridgewater NJ 08807 908 977-9900 false false false false Common Stock, par value $0.01 per share INSM NASDAQ false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2018832d2_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "tm2018832d2_8k.htm" ] }, "labelLink": { "local": [ "insm-20200507_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "insm-20200507_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "insm-20200507.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "insm", "nsuri": "http://insmed.com/20200507", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2018832d2_8k.htm", "contextRef": "From2020-05-06to2020-05-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://insmed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2018832d2_8k.htm", "contextRef": "From2020-05-06to2020-05-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } XML 15 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover
May 07, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 07, 2020
Entity File Number 000-30739
Entity Registrant Name INSMED INCORPORATED
Entity Central Index Key 0001104506
Entity Tax Identification Number 54-1972729
Entity Incorporation, State or Country Code VA
Entity Address, Address Line One 700 US Highway
Entity Address, Address Line Two 202/206
Entity Address, City or Town Bridgewater
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08807
City Area Code 908
Local Phone Number 977-9900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol INSM
Security Exchange Name NASDAQ
Entity Emerging Growth Company false